You are here: Home » PTI Stories » National » News
Business Standard

World's 1st malaria vaccine gets regulatory nod from EMA

Press Trust of India  |  London/Geneva 

The world's first malaria vaccine today cleared one of the final hurdles as it received a positive scientific opinion from European regulators and now awaits approval from the WHO before it could be administered within the next few years across Africa.

The vaccine, named Mosquirix, was given the green light by London-based European Medicines Agency after more than 30 years of research, detailed in 230,000 pages of data.

The vaccine will be examined by the WHO which will give its recommendation in November this year, and if approved, could be administered to children across Africa within the next few years.

"This is the first time ever that a malaria vaccine has got to the point of being reviewed by a regulatory authority. So this is a big step forward and we welcome the positive opinion given by the European Medicines Agency (EMA). This is an opinion and not a regulatory approval," said Gregory Hartl, WHO's spokesperson for Avian Influenza and other epidemic diseases.

"What happens next is that the assessment from EMA will be reviewed by WHO in October and we will look at the vaccine from the point of view of public health," Hartl said in Geneva.

The WHO said the vaccine will be reviewed for feasibility in field situations in developing countries, its affordability and its cost effectiveness.

"It's massively significant," said Allan Pamba, vice president for pharmaceuticals in East Africa for GlaxoSmithKline (GSK), which has spent more than USD 356 million to date on finding a vaccine.

Researchers and pharmaceutical companies have been trying to develop malaria vaccines for decades. Some vaccines which had been developed in the past failed in their phase three trials.

"It is a big development but it's not finished yet and certainly our work starts now," said Hartl.

Malaria kills around 600,000 people a year worldwide, most of them children under five in sub-Saharan Africa.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, July 24 2015. 18:42 IST